DOCSLIB.ORG

Medimmune Delivering the Next Wave of Scientific Innovation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medimmune Delivering the Next Wave of Scientific Innovation MedImmune Delivering the next wave of scientific innovation Bahija Jallal, Executive Vice President, MedImmune Building on the fundamentals Next wave of science 1 – MedImmune MedImmune has a 25+ year history in biologics; pioneering scientists are still driving discoveries today RespiGam 1996 2002 Gail Wasserman, PhD Mike McCarthy, MD, MPH, MS Tris Vaughan, PhD 1998 Biopharmaceutical Dev. Infectious Diseases / Vaccines Antibody Discovery & Pennsylvania State Uni. U. Maryland University College Protein Engineering Montclair State Uni. Georgetown U. School of Med. 2011 University of Toronto University of Leeds 1998 2003 2006 JoAnn Suzich, PhD Mark Schenerman, PhD Hong Jin, PhD Infectious Disease / Biopharmaceutical Dev. Infectious Diseases / Vaccines Cornell University Vaccines Purdue University University of Florida Northwestern Uni. 2009 2012 Glasgow Uni. 2 – MedImmune MedImmune continues to attract world class scientists with strong expertise in areas of interest Yong-Jun Liu, MD, PhD Jack Ratchford, MD Head of Research Neuro-Immunology Baylor Research Institute Chief Scientific Johns Hopkins U. School of Medicine Officer and Director of Immunology Columbia U. College of Physicians and Research Surgeons David Howe, MD Jacob Wesley, PharmD, MS Autoimmunity Oncology Cornell University Johns Hopkins University University of Toronto University of Maryland Edinburgh U. Medical School Brett Hall, PhD Eliezer Katz, MD Translational Science - Oncology Neuro-Inflammation West Virginia University U. of Massachusetts Medical Center Ohio State University Hebrew U. - Hadassah Medical School Jiping Zha, MD, PhD John Kurland, PhD Translational Medicine - Oncology Translational Medicine – Oncology U. Texas Southwestern Med Ctr Dallas Cold Spring Harbor Laboratory Harvard Medical School U. Texas M. D. Anderson Cancer Center University of Tennessee Shanghai Medical University 3 – MedImmune MedImmune has a collaborative work environment where staff are encouraged to publish & innovate 4 – MedImmune Our sustainable pipeline is built on excellence in science Expertise in Strength Excellence in technology & in translational protein immunology research engineering 5 – MedImmune MedImmune’s strong heritage in immunology is leveraged across therapeutic areas Respiratory, inflammatory, Oncology: Immuno- autoimmune diseases oncology therapies Tempering overactive or Harnessing / activating the inappropriate immunity immune system Immune system Chronic inflammation Chronic inflammation Essential for combat of (unfolded protein response) pathogens Neurological Cardiovascular & Infectious diseases / diseases metabolic diseases vaccines 6 – MedImmune Disease biology drives our tech focus: Novel (non mAb) drug formats represent >50% of our research portfolio Deep “toolkit” of non-mAb …and growing as a proportion of the approaches… preclinical pipeline 60% Ab-drug Ab Bispecific conjugate mimetic Ab 50% Dual peptide 40% 30% mAb 20% (+YTE) Peptide mAb- fusion 10% 0% Jan Jan Jan Jan Jan Sep -10% 2010 2011 2012 2013 2014 2014 Preclinical (MsB-CD) 7 – MedImmune Personalised healthcare is a core principle: More than 80% of our biologics portfolio employs a PHC approach Example: PD-L1 PD-L1 protein expression may not be an absolute determinant of response…we leverage multiple tools to identify responders Antibody and TCR diversity Circulating Genomics Flow cytometry Tumour cell Tumour cells and proteomics Target expression 8 – MedImmune Building on the fundamentals Next wave of science 9 – MedImmune MedImmune’s Research & Early Development portfolio is robust with emphasis on core TAs Lead Optimisation Pre-clinical Phase I Phase IIa Phase IIb MEDI3617 MEDI-551 MEDI2070/AMG-139 anifrolumab Onc RIA Onc Ang2; GBM CD19; MS IL-23p19; Crohn’s IFNaR; SLE MEDI-565 MEDI5872/AMG-557 tralokinumab sifalimumab Onc RIA Onc CEA BiTE; GI tumors B7RP1; SLE IL-13; IPF IFNa; SLE MEDI6469 MEDI4920 MEDI-551 mavrilimumab Onc RIA Onc mOx40; Solid tumors CD40L;Sjögren’s CD19; CLL, DLBCL GM-CSFR; RA MEDI6383 MEDI6012 MEDI-573 MEDI7183/AMG-181 Onc RIA Onc OX40 FP; Solid Tumors LCAT; ACS IGF; MBC A4b7; UC, Crohn’s MEDI4736+BRAF/MEK MEDI8111 MEDI4736 PD-L1 brodalumab Onc RIA Onc PD-L1; melanoma FII; trauma bleeding solid tumours IL-17R; severe asthma MEDI4736 + Treme MEDI4893 MEDI4736+Iressa MEDI9929/AMG-157 Onc RIA Onc PDL1/CTLA4 solid tumor staph alpha toxin PD-L1/EGFR; NSCLC TSLP; asthma MEDI0680 MEDI-550 moxetumomab Onc RIA Onc PD-1; solid tumors pandemic flu library CD22; pALL MEDI-551+CD20 MEDI8897 Onc RIA Onc DLBCL RSV anti-F NG MEDI4736/0680 MEDI7510 Onc RIA Neuro PD-L1/PD-1; NSCLC older adult RSV vaccine MEDI6469/4736 MEDI3902 Onc CVMD RIA solid tumors PcrV/Psl bispecific MEDI4736+AZD9291 PRVV Onc CVMD RIA PD-L1/EGFR; NSCLC RSV prevention MEDI0639 Onc CVMD RIA DLL-4; SCLC MEDI1814 Onc CVMD RIA A-Beta NG; AD Onc CVMD RIA Onc CVMD RIA Onc CVMD RIA Oncology Neuro CVMD CVMD RIA Neuro CVMD ID/Vax CVMD Neuro CVMD ID/Vax ID / Vaccine Neuro ID/Vax ID/Vax Neuroscience ID/Vax ID/Vax 10 – MedImmune MedImmune’s programme for Sjögren's employs the novel Tn3 scaffold to avoid mAb-related complications MEDI4920: Target • Blocks co-stimulatory path for CD40L on T cells to bind to CD40 on B cells Rationale • mAbs efficacious in animal models Platelet Aggregation • mAbs tested in the clinic with some 400nM 200nM 100nM Biogen 5c8 positive data, but terminated due to blood clots MEDI4920 Differentiation • Tn3 scaffold is a novel non-mAb Biogen 5c8 technology; avoids blood clotting characteristic of anti-CD40L mAbs aggregation Percent • First small protein technology at MEDI to enter clinic 11 – MedImmune MedImmune’s novel ADC candidate employs the PBD payload and demonstrates early efficacy against cancer ADC: Target H1975 NSCLC xenograft: Tumor regression with single dose ADC • Cancer stem cell target • Limited expression in normal tissues Indication • Overexpressed in several tumor types – Lung – Breast Candidate • Novel ADC conjugated with PBD payload Best Scientific • Tumor regression after single dose Innovation: 12 – MedImmune We are building our early ADC pipeline; vigorously pursuing a broad range of oncology targets ADC research portfolio 2015 2016 2017 ADC1 IND ADC2 IND ADC3 IND ADC4 IND ADC5 IND ADC6 IND ADC7 IND ADC8 IND ADC9 IND • Forecast is subject to project attrition • Target discovery activities have launched additional projects for IND delivery beyond 2017 13 – MedImmune MedImmune is progressing a next generation, extended half-life mAb for RSV MEDI8897 : Target • Novel, neutralizing epitope on the RSV F protein, located on the surface of the virion Serum PK in NHP Model Indication • Passive immunization of all infants entering their 1st RSV season • Children with chronic lung or chronic heart disease entering their 1st and 2nd RSV seasons for the prevention of lower respiratory tract illnesses Candidate • Binds to novel epitope, neutralizing RSV • Extended half-life based on proprietary, clinically validated YTE technology 14 – MedImmune MedImmune is pursuing an innovative multi-functional, bi-specific approach for the treatment of P. aeruginosa MEDI3902 : Target #1: PcrV – Virulence • Prevents toxin injection anti-PcrV into host cells anti-Psl • High affinity mAb to low density target Target #2: Psl – Colonisation Persistence • Dual mechanism of action: Clearance and blocks cell adherence • Lower affinity mAb to high density target 15 – MedImmune Protein X presents an opportunity to deliver a step change in diabetes therapy Protein X: Target 18 16 • Novel protein with novel mechanism of Veh action 14 ** Low 12 * Glucose (mM) Indication 10 High *** *** 8 * ** • Type 2 Diabetes * *** 6 • Goal 0 10 20 30 – Dose-dependent reductions in blood sugar Days of treatment – Significantly improved islet health Data are presented as mean±SEM n=28 (veh), n=22 (Prot-X groups) – Improved insulin sensitivity Vehicle Control 3 mg/kg/d Prot-X Candidate • May regulate pancreatic β-cell function 16 – MedImmune Summary We have created a vibrant environment, promoting innovation and scientific excellence We have a robust, balanced, sustainable portfolio We are moving beyond mAbs, pioneering the next wave of biologics innovation 17 – MedImmune We push the boundaries of science to deliver life-changing medicines 18 – MedImmune Q&A Briggs Morrison, moderator Mene Pangalos Bahija Jallal .
Load more

Recommended publications
  • The Scientific Organizing Committee Gratefully Acknowledges the Pharmaceutical and Biotechnology Industry for Their Generous Support of WCBP 2019
    The Scientific Organizing Committee gratefully acknowledges the pharmaceutical and biotechnology industry for their generous support of WCBP 2019: Strategic Diamond Program Partners F. Hoffmann-La Roche Ltd. Genentech, a Member of the Roche Group Strategic Platinum Program Partners Amgen Inc. Biogen MedImmune, A member of the AstraZeneca Group Strategic Gold Program Partners Eli Lilly and Company Merck & Co., Inc. Novo Nordisk A/S Pfizer, Inc. Strategic Silver Program Partner Sanofi 1 Gold Program Partner Bill and Melinda Gates Foundation Silver Program Partners BioMarin Pharmaceutical Inc. Bristol-Myers Squibb Company GlaxoSmithKline Jazz Pharmaceuticals Bronze Program Partner Seattle Genetics, Inc. Friend of CASSS Janssen R&D, LLC 2 The Scientific Organizing Committee gratefully acknowledges the Program Partners and Exhibitors for their generous support of WCBP 2019: Diamond Program Partners Agilent Technologies Catalent Pharma Solutions Eurofins Pharma Discovery Services ProteinSimple, a Bio-Techne brand Thermo Fisher Scientific Waters Corporation Platinum Program Partners BioAnalytix SCIEX Bronze Program Partner Bruker Corporation 3 The Scientific Organizing Committee gratefully acknowledges the Exhibitors for their generous support of WCBP 2019: Exhibitor Partners 908 Devices Inc. NanoImaging Services Agilent Technologies New England Biolabs Associates of Cape Cod, Inc. Postnova Analytics Inc. BioAnalytix Inc. Pressure BioSciences Inc. Bruker Corporation Protein Metrics, Inc. Catalent Pharma Solutions ProteinSimple, a Bio-Techne brand Charles River Laboratories ProZyme, A part of Agilent Covance, Inc. RedShift BioAnalytics, Inc. Cygnus Technologies Rockland Immunochemicals, Inc. Envigo SCIEX Eurofins BioPharma Product Testing SGS Life Science Services Eurofins Pharma Discovery Services Shimadzu Scientific Instruments, Inc. FortéBio - Biologics by Molecular Devices Thermo Fisher Scientific GE Healthcare Life Sciences U.S.
    [Show full text]
  • The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry
    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field.
    [Show full text]
  • United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) N.A. East Anton, Andover, Hampshire SP10 5RG England (Address of principal executive offices) (Zip Code) 44 1264 333455 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depository Shares, each representing Nasdaq National Market 3 Ordinary Shares, 5 pence nominal value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ፤ No អ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500
    Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500 www.dyax.com Other Offices Dyax SA, Liege, Belgium ADVANCING NOVEL THERAPEUTIC PRODUCTS Dyax Corp. Annual Report 2003 Corporate Information Dyax Achievements 2003 Dyax Goals 2004 Directors Executive Officers and Stock Listing Henry E. Blair Key Employees Common stock has been traded on the Nasdaq Stock Market Advances in Clinical Development Clinical Development Chairman, President and Henry E. Blair* under the symbol DYAX since our initial public offering in Milestones Chief Executive Officer, Chairman, President and August 14, 2000. DX-88/Hereditary Angioedema Dyax Corp. Chief Executive Officer DX-88/Hereditary Constantine E. Stephen S. Galliker, CPA* The following table gives the quarterly high and low sales G Completed 9-patient Phase II trial, met primary endpoints Angioedema Anagnostopoulos, Ph.D. EVP Finance and prices of our common stock for the last three years. G Genzyme Corporation joined Dyax as joint venture partner Managing General Partner, Administration and G Complete Phase II 2001 2002 2003 G Gateway Associates, LP Chief Financial Officer Completed 3 of 4 dose cohorts in 48-patient Phase II EDEMA1 trial EDEMA1 study High Low High Low High Low G Susan B. Bayh, J.D. Lynn G. Baird, Ph.D.* Initiated Phase II EDEMA2 trial G Periodically observe James W. Fordyce SVP Development First Quarter $20.94 $6.56 $11.38 $3.10 $2.25 $1.52 G Orphan Drug designation granted in U.S. and Europe effects of repeat dosing in Phase II EDEMA2 Managing Partner, Robert C. Ladner, Ph.D. Second Quarter $19.99 $6.81 $ 4.68 $3.20 $4.90 $1.67 Fordyce & Gabrielson, LLC SVP and Chief DX-88/On-Pump Open Heart Surgery (CABG) study Third Quarter $21.24 $6.05 $ 4.20 $1.65 $7.50 $2.58 Mary Ann Gray, Ph.D.
    [Show full text]
  • 2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
    2016 Medicines in Development for Rare Diseases A LIST OF ORPHAN DRUGS IN THE PIPELINE Autoimmune Diseases Product Name Sponsor Official FDA Designation* Development Status Actemra® Genentech treatment of systemic sclerosis Phase III tocilizumab South San Francisco, CA www.gene.com Adempas® Bayer HealthCare Pharmaceuticals treatment of systemic sclerosis Phase II riociguat Whippany, NJ www.pharma.bayer.com ARA 290 Araim Pharmaceuticals treatment of neuropathic pain in patients Phase II Tarrytown, NY with sarcoidosis www.ariampharma.com ARG201 arGentis Pharmaceuticals treatment of diffuse systemic sclerosis Phase II (type 1 native bovine skin Collierville, TN www.argentisrx.com collagen) BYM338 Novartis Pharmaceuticals treatment of inclusion body myositis Phase III (bimagrumab) East Hanover, NJ www.novartis.com CCX168 ChemoCentryx treatment of anti-neutrophil cytoplasmic Phase II (5a receptor antagonist) Mountain View, CA auto-antibodies associated vasculitides www.chemocentryx.com (granulomatosis with polyangitis or Wegener's granulomatosis), microscopic polyangitis, and Churg-Strauss syndrome * This designation is issued by the FDA's Office of Orphan Products Development while the drug is still in development. The designation makes the sponsor of the drug eligible for entitlements under the Orphan Drug Act of 1983. The entitlements include seven years of marketing exclusivity following FDA approval of the drug for the designated use. Medicines in Development: Rare Diseases | 2016 1 Autoimmune Diseases Product Name Sponsor Official FDA
    [Show full text]
  • An Emerging National Resource for Clinical Research and Your Healthcare Partner in Personalized Medicine Innovation
    An Exclusive Membership Look into Colorado To visualize improving the world around us Fisher Scientifi c, part of Thermo Fisher Scientifi c, the world leader in serving science, is pleased to have the opportunity to partner with the Colorado BioScience Association and act as primary supplier of laboratory products, safety supplies, equipment, chemicals, reagents and a host of services. Fisher Scientifi c understands today’s challenging environment and has capabilities that align with CBSA’s strategic goals going beyond just providing products to o ering Colorado BioScience Association members access to customized programs to fi t their specifi c needs from start-up to scale-up. 1.800.766.7000 • Fax: 1.800.926.1166 • www.fi shersci.com 2 BIOSCIENCECOLORADO 2014-2015 Litho in U.S.A. 13_0280 JJ/KJ COLOR ADO 2014-2015 Drawing People & Data Together to Benefit Human Health 10 22 26 14 6 CONTENTS 06 Mobile Health in Colorado: Where “Big Data” Sparks Big Ideas 10 Biodesix Harnesses Machine Learning and Analytics to Tackle Multivariate Diagnostics 14 Bioscience in Colorado Continues to Shine with U.S. Senator Michael Bennet 16 Color ado Life Science Assets: A Sophisticated Repertoire of Clinical-Stage Therapeutic, Device and Diagnostic Products 22 Webb-Waring Biomedical Research Program 26 F ound in Translation: Rocky Mountain Lions Eye Institute Translational Research Programs Focus on Innovative Treatment of Eye Diseases 30 Connecting the Dots: Tech Transfer Offices Connect Research and Marketplace to Stimulate the State's Economy 33 Colorado by the Numbers: Financing and Acquisitions 36 Grant Programs: Innovation Engines 48 Colorado Bioscience Industry Directory 2014-2015 BIOSCIENCECOLORADO 3 We Know Workforce elcome to the Colorado BioScience Association’s eleventh anniversary edition of Bioscience Colorado.
    [Show full text]
  • Immunocore and Medimmune Announce New Collaboration to Conduct Immuno-Oncology Combination Trials in Melanoma
    PRESS RELEASE – IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases, and MedImmune, the global biologics research and development arm of AstraZeneca, today announced that they have entered into a second collaboration. Under the terms of the agreement, Immunocore will conduct a Phase Ib/II clinical trial combining MedImmune’s investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, Immunocore’s lead T-cell receptor based investigational therapeutic, for the potential treatment of patients with metastatic melanoma. MedImmune has an exclusive relationship with Immunocore for the development of IMCgp100 in combination with MEDI4736 and/or tremelimumab, and will have first right of negotiation for the future commercial development of these combinations for tumours expressing gp100. Immunocore and MedImmune will collaborate to establish a dosing regimen for IMCgp100 combined with MEDI4736 and/or tremelimumab, as part of the Phase Ib study. The Phase II study will assess the safety and efficacy of the different combinations. The companies have a pre-existing research collaboration and licensing agreement, announced in January 2014, to develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. “We are pleased to expand our partnership with Immunocore, a leader in the discovery and development of novel T-cell receptor-based drugs, to include this combination clinical trial in melanoma,” said Dr. Ed Bradley, Senior Vice President and Head of the Oncology Innovative Medicines unit, MedImmune.
    [Show full text]
  • Summit for Clinical Ops Executives
    Organized by Register Today! FINAL AGENDA 7th Annual February 23 - 25, 2016 | Hyatt Regency Miami, Miami, FL Back in SUMMIT FOR CLINICAL OPS EXECUTIVES Miami! February 23-24 February 24-25 Global Site Selection, Feasibility Assessment, Improving Site-Study Activation and Performance Operations and Site Management Patient Engagement, Enrollment and Retention through Enrollment Planning and Patient Recruitment Communities and Tech Clinical Trial Forecasting and Budgeting Managing Outsourced Clinical Trials Implementing Risk-Based Monitoring (Part 1) Implementing Risk-Based Monitoring (Part 2) Clinical IT Strategy and Governance Clinical Data Technology and Integration Managing Late Stage Research, Observational Leveraging Existing Data for Clinical and Studies and Registries Observational Research Symposia - February 23-24 Managing Biomarker-Driven Clinical Trials NEW Clinical Research Statistics for Non-Statisticians NEW Event Features BEST 12 Conferences Clinical Informatics News Best Practices Awards P R S 2 Plenary Keynote Sessions Dedicated Exhibit Hall Hours & A E C T I C Networking Functions 3 Short Courses RAC RAC RAC P T P T P T T IC T IC T IC S E S E S E Interactive Breakout Discussions 2 New Symposia E S E S E S B B B 2 n 0 1 o i 2 2 4 t 0 E 0 R H n 1,000+ Industry Leaders Expected in 2016 1 E o e 1 E 4SCOPEsummit.comn M 4 N W I N N o r a b l e N O M I PREMIER SPONSORS Event-at-a-Glance Monday, February 22, 2016 Pre-Conference Short Courses (Optional, Separate Registration Required) 1.
    [Show full text]
  • The Future of Biomanufacturing
    THE FUTURE OF BIOMANUFACTURING WELCOME TO A PLACE THAT DELIVERS. HEADER 2 | BIOMANUFACTURING WELCOME TO EUROPE’S MOST SIGNIFICANT CLUSTER OF BIOMANUFACTURING. Liverpool City Region is home to the world’s biggest pharmaceutical players. It is also one of the world’s longest established biomanufacturing centres, chosen by the UK government in the 1940s for the largest penicillin manufacturing plant in the world. Major companies continue to build on this long-tradition and reinvest in new world-class facilities. Our formula for pharma manufacturing success is clear. Liverpool City Region sits at the centre of the UK’s chemical engineering industry; is part of a major centre for health and life sciences and is driving the advanced manufacturing sector through digital innovation. The convergence of these assets has a catalytic impact on the availability of the science, technology and engineering talent that underpins biomanufacturing. Most importantly though, a committed partnership of local organisations is supporting existing manufacturers and the wider supply-chain, through programmes to invest in the infrastructure, facilities and skills that the sector needs to succeed. Welcome to your future-proofed business location. BIOMANUFACTURING | 3 M65 M 6 SEFTON M 6 2 6 6 M M 6 1 M58 62 M M 6 GLASGOW M602 EDINBURGH M MANCHESTER 5 7 M 6 GLOBAL 0 TRADE KNOSLEY ROUTES ST. HELENS 0 6 M NEWCASTLE LIVERPOOL M 62 6 15 M 10 11 M62 12 14 13 HALTON LIVERPOOL CITY REGION LEEDS 56 MANCHESTER HULL M 1 AIRPORT MANCHESTER 7 RIVER 4 M MERSEY 2 9 5 8 SHEFFIELD IRRAL 5 3 3 M LIVERPOOL JOHN 6 LENNON AIRPORT NOTTINGHAM AL CAN 6 SHIP STER CHE MAN BIRMINGHAM 6 M5 CARDIFF BRISTOL LONDON PLYMOUTH SOUTHAMPTON 4 | BIOMANUFACTURING M65 M 6 SEFTON M 6 2 6 6 M M 6 1 M58 62 M M 6 M602 M MANCHESTER 5 7 M 6 GLOBAL 0 TRADE KNOSLEY ROUTES ST.
    [Show full text]
  • Shire: a Focused Global Pharmaceutical Company Focusing on a Bright Future Shire Pharmaceuticals Group Plc the Shire Mission
    Shire Pharmaceuticals Group plc Annual review and summary financial statement 2003 Shire: a focused global pharmaceutical company Focusing on a bright future Shire Pharmaceuticals Group plc The Shire mission Our mission is to become the leading company in meeting the needs of the specialist physician. We want to achieve this by developing and Contents 01 Financial highlights marketing products of the highest quality 02 Chairman’s statement 04 Chief Executive Officer’s review for the treatment of serious diseases, 06 Product portfolio 07 Product development pipeline which are treated by medical specialists. 08 Operating review 22 CSR: Corporate and social responsibility 24 Financial review We aim to provide high quality and effective 28 Board of Directors 30 The Executive Committee products that enhance the health and 32 Directors’ remuneration report 44 Corporate governance quality of life of people around the world statement Financial Statements and contribute to the long-term business 48 Statement of Directors’ responsibilities – Report of success of our Company, to the benefit independent auditors 49 Consolidated balance sheets 50 Consolidated statement of all our stakeholders. of operations 51 Consolidated statements of changes in shareholders’ equity We are driven by the needs of all our 52 Consolidated statements of cash flows stakeholders: patients, their families and 53 Notes to the consolidated financial statements 87 Five-year review caregivers, doctors and medical specialists, 88 Summary financial statement 93 Notes to summary employees and partner companies, the financial statement community in which we live and work and, Other 94 Shire head office and main operating locations of course, our shareholders.
    [Show full text]
  • Medimmune Advancing Science for Better Health
    MedImmune Advancing Science for Better Health Annual Report 2005 On the Cover SCIENCE, TECHNOLOGY AND INNOVATION ARE AT THE HEART OF MEDIMMUNE’S RESEARCH AND DEVELOPMENT EFFORTS, HELPING TO PROVIDE THE ADVANCES IN MEDICINE NEEDED FOR PATIENTS. FROM LEFT TO RIGHT, SUSAN WILSON, RESEARCH MANAGER I, WENDY WHITE, SENIOR SCIENTIST I, FRAN PALMER-HILL, RESEARCH MANAGER I, AND JOANN SUZICH, SENIOR DIRECTOR, MOLECULAR BIOLOGY AND BIOCHEMISTRY, ARE MEMBERS OF THE ORIGINAL TEAM AT MEDIMMUNE WHO PIONEERED THE DEVELOPMENT OF VIRUS-LIKE PARTICLE TECHNOLOGY IN THE MID-1990s THAT IS NOW INCORPORATED INTO HUMAN PAPILLOMAVIRUS (HPV) VACCINES IN DEVELOPMENT AT GLAXOSMITHKLINE (GSK). THIS HPV VACCINE TECHNOLOGY IS AN EXAMPLE OF OUR CONTINUING PRODUCT DEVELOPMENT PROCESSES THAT, WE BELIEVE, MAY RESULT IN SCIENTIFIC ADVANCES IN OTHER AREAS, SUCH AS INFLUENZA VACCINES AND THE TREATMENT AND PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV). Financial Highlights (in millions, except per share data) 20051,2 20042 2003 20023,4 20014 CONSOLIDATED STATEMENT OF OPERATIONS DATA Total Revenues $1,244 $1,141 $1,054 $ 853 $ 621 Gross Profit 884 758 703 589 443 Research & Development 385 327 156 148 83 Net (Loss) Earnings (17) (4) 183 (1,098) 149 Diluted (Loss) Earnings Per Share (0.07) (0.02) 0.72 (4.40) 0.68 CONSOLIDATED BALANCE SHEET DATA Cash and Investments $1,472 $1,706 $1,900 $ 1,423 $ 778 Total Assets 2,780 2,564 2,795 2,188 1,237 Long Term Debt, including current portion5 506 507 682 218 10 Total Shareholders’ Equity 1,571 1,675 1,699 1,677 1,044 1 Includes charges for acquired in-process research and development (IPR&D) in connection with the Company’s acquisition of Cellective on October 14, 2005.
    [Show full text]
  • Sensitivity Analyses of Time to Adjudicated Attacks in the N
    Sensitivity analyses of time to adjudicated attacks in the N-MOmentum study: P1652 a randomized, placebo-controlled, double-masked trial in patients with neuromyelitis optica spectrum disorder Bruce AC Cree,1 Jeffrey L Bennett,2 Ho Jin Kim,3 Brian Weinshenker,4 Sean J Pittock,4 Dean Wingerchuk,5 Kazuo Fujihara,6 Friedemann Paul,7 Gary Cutter,8 Romain Marignier,9 Ari Green,10 Orhan Aktas,11 Hans-Peter Hartung,11 Fred D Lublin,12 Maureen A Mealy,13 Jorn Drappa,13 Gerard Barron,14 Soraya Madani,13 Dewei She,13 Daniel Cimbora,13 William Rees,13 John N Ratchford13 and Eliezer Katz,13 on behalf of the N-MOmentum Study Investigators 1UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA; 2University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, CO, USA; 3Research Institute and Hospital of the National Cancer Center, Seoul, South Korea; 4Mayo Clinic, Rochester, MN, USA; 5Mayo Clinic, Scottsdale, AZ, USA; 6Department of Multiple Sclerosis Therapeutics, Fukushima Medical University and Multiple Sclerosis and Neuromyelitis Optica Center, Southern Tohoku Research Institute for Neuroscience, Koriyama, Japan; 7Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany; 8University of Alabama at Birmingham, Birmingham, AL, USA; 9Lyon University Hospital, Lyon, France; 10UCSF Weill Institute for Neurosciences, Department of Neurology and Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA; 11Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; 12Icahn School of Medicine at Mount Sinai, New York, NY, USA; 13Viela Bio, Gaithersburg, MD, USA; 14Viela Bio, Cambridge, UK INTRODUCTION Figure 3.
    [Show full text]